ASTCT

ASTCT's New Investigator Awards (NIAs) are designed to encourage clinical and/or laboratory research by young investigators in the field of hematopoietic cell, cell therapy and/or gene therapy. Apply now or share this opportunity: ow.ly/Te6T50WuV9O

This 'Transplantation and Cellular Therapy' study identified advanced age, high comorbidities, UCB, & PTCy haploidentical HCT as factors significantly benefiting survival with LTV. The heterogeneity of LTV survival benefits showed the importance of personalized clinical decisions. ow.ly/LVe650WsP3E

🌟 For the first time, ASTCT is accepting abstracts to the Gene Therapy Summit! Be among the first researchers to share your gene therapy findings at this landmark meeting. Submit your abstract by Aug. 10: ow.ly/ocbb50Ws2MZ

Join ASTCT as a member with extended membership now through July 15 to be entered to win complimentary registration to your choice of the 2025 Clinical Education Course (CEC) or the 2026 Fundamentals of HCT Training Course! Learn more & join today: ow.ly/t7mO50Wkytj

Join ASTCT as a member with extended membership now through July 15 to be entered to win complimentary registration to your choice of the 2025 Clinical Education Course (CEC) or the 2026 Fundamentals of HCT Training Course! Learn more & join today: ow.ly/z5KT50Wkytl

ASTCT & CancerNetwork organized an X Space hosted by Rahul Banerjee; Taha Al-Juhaishi & Muhammad Salman Faisal to discuss key presentations and abstracts of interest at the ⁠2025 ASCO Annual Meeting⁠. Listen now to catch up on what was discussed: ow.ly/4KJt50Wasku

Great @astct.bsky.social & @sitcancer.bsky.social Solid Tumor Summit in Chicago yesterday. Important discussions with multiple stakeholders including academia industry and community practice to bring novel cellular therapies to patients with solid tumors.

Deadline extended ‼️ The deadline to submit an abstract for the ASTCT + EBMT #RelapseConference25 to June 2. Showcase your relapse post-transplant-related findings this fall in Madrid: ow.ly/7YN850VSX4n

Applications are open for the 2026 International Trainee Observership Program. One international trainee from a low/mid-income country will participate in 4-week-long observership at the @uofcahealth.bsky.social.

📆 Deadline to apply: Friday, June 13
ow.ly/Ih0650VK0vn #MedSky #HCT #celltherapy

ASTCT is excited to unveil our improved practice guidelines app! Features include:
✅ Integration of a GVHD tool to diagnose & score
✅ Filter easily b/n HCT & cell therapy
✅ Built-in calculators for critical risk factors & diagnosis
✅ Easy access to ASTCT practice guidelines

#MedSky #OncSky #HemeSky

You won't want to miss this webinar—on May 1 experts from
@mskcancercenter.bsky.social & @fredhutch.bsky.social
will cover the rising concern of measles outbreaks and their unique risks for our patient populations. Register for free: ow.ly/ptUx50VF25j #MedSky #MedEd

Ide-Cel Displays Potential in Myeloma After Suboptimal Response to Frontline ASCT and Maintenance Alfred L. Garfall, MD, discusses the role of ide-cel in patients with multiple myeloma following suboptimal responses to upfront auto-HCT.

Ide-Cel Displays Potential in Myeloma After Suboptimal Response to Frontline ASCT and Maintenance @pennmedicine.bsky.social @astct.bsky.social #Tandem25
#MultipleMyeloma #MMSM
www.onclive.com/view/ide-cel...

Now is your chance to make an impact among HCT & cell therapy researchers — submit an abstract to the ASTCT + EBMT Relapse Conference! Showcase your relapse post-transplant-related findings this fall in Madrid: ow.ly/O50I50Vsuia

ASTCT's journal, 'Transplantation and Cellular Therapy,' recently released a new supplement dedicated to the latest research, challenges & innovations in Tumor-Infiltrating Lymphocyte (TIL) therapy, supported through an educational grant provided by Iovance Biotherapeutics: ow.ly/MviL50VlXTi

The Fundamentals of HCT Training Course provides a broad intro to #HCT & cellular immunotherapy; it incorporates case-based learning to emphasize the application of concepts taught, with a strong focus on pharmacotherapeutic management. Register now or share: ow.ly/j69f50QIyfQ

Impactful work and leadership by @astct.bsky.social to reduce regulatory burden for centers offering #CellTherapy #CARTcells

🧬 #Tandem25 Recap: This session explored the promise of next-generation sequencing in TID, while also addressing key challenges.

Learn more: ow.ly/MBjM50V6jnE

Improvement in autoimmune diseases after CAR T therapy. Of patients with active autoimmune disease on treatment at time of CAR T, 4 patients had an improvement of their autoimmune disease, 3 stable disease, and 1 worsening. The patients who benefitted had SLE, APS, RA, and CAD.

There’s been much discussion about CAR T for severe autoimmune disease, incl. lupus & MS. What can we learn about how that might work from patients who have both cancer & autoimmune disease and get B-/plasma-cell directed CAR T?

From Jennifer Huang @fredhutch.bsky.social #Tandem25 #OncSky #RheumSky

#tandem25 #bmtsm Perales: recent TCT journal issue dedicated for subspecialty mgmt of cGVHD. Good ref for ophthalmology, pulm, derm, etc.

Congratulations to @sghmd.bsky.social, the 2025 recipient of the Lukas D. Wartman GVHD Achievement Award. This award recognizes Dr. Holtan for her exceptional work and dedication to advancing GVHD patient care. Dr. Lukas D. Wartman personally bestowed the award to Dr. Holtan at #Tandem25.

Fred Hutch at #Tandem25: Catch presentations from Dr. Jennifer Adair, Elizabeth Krantz and Dr. Jennifer Huang on global access to #genetherapy, #cartcelltherapy and more. Details: bit.ly/4jW3ukj

Orca-T’s Display of Decreased NRM, Increased RFS May Contribute to Favorable OS in Hematologic Malignancies Orca-T improved OS vs post-transplant cyclophosphamide in a retrospective analysis of patients with hematologic malignancies.

Orca-T’s Display of Decreased NRM, Increased RFS May Contribute to Favorable OS in Hematologic Malignancies @astct.bsky.social #TANDEM25 #oncology www.onclive.com/view/orca-t-...

During his presidential transition Dr. David Porter, the new president of ASTCT, reaffirms the society’s commitment to advance patient care in the HCT, cell therapy and gene therapy field at #Tandem25.

Cilta-Cel Provides Deep MRD Negativity in Lenalidomide-Refractory Multiple Myeloma Cilta-cel led to rapid and deep MRD negativity in patients with lenalidomide-refractory multiple myeloma.

Cilta-Cel Provides Deep MRD Negativity in Lenalidomide-Refractory Multiple Myeloma @mayocliniccancer.bsky.social @astct.bsky.social #Tandem25 #mmsm #oncology www.onclive.com/view/cilta-c...

🏆 The #Tandem25 Awards and Lectures will honor four individuals for their contributions and achievements in the field of transplant therapy.

Learn more: ow.ly/xn3m50V0EBO

At #Tandem25: @drkomanduri.bsky.social
accepts the ASTCT advocacy award. Congratulations Dr. Komanduri, we commend you for your dedication to advancing our field!

Orca-T Is a Safe Addition to HSCT-RIC in Advanced Hematologic Malignancies Orca-T with HSCT-RIC displayed robust and early donor myeloid and T-cell engraftment in patients with advanced hematologic malignancies.

Orca-T Is a Safe Addition to HSCT-RIC in Advanced Hematologic Malignancies
@astct.bsky.social #TANDEM25 #heme #oncology
www.onclive.com/view/orca-t-...

Axatilimab Displays Durable Responses in cGVHD Irrespective of Number of Prior Lines of Treatment Axatilimab displayed similar efficacy regardless of the number of prior lines of therapy in chronic graft-versus-host disease.

Axatilimab Displays Durable Responses in cGVHD Irrespective of Number of Prior Lines of Treatment @astct.bsky.social #TANDEM25 #hematology #oncology #GVHD
www.onclive.com/view/axatili...

Orca-Q Shows Promise in High-Risk Hematologic Cancers and BFT Conditioning May Synergize With the Agent One-year follow-up data from an ongoing phase 1 study showed that Orca-Q offered similar benefits as T-cell depletion, without the typical compromises seen.

Orca-Q Shows Promise in High-Risk Hematologic Cancers and BFT Conditioning May Synergize With the Agent @cityofhope.bsky.social @astct.bsky.social #TANDEM25 #hematology #oncology
www.onclive.com/view/orca-q-...

Friday at #Tandem25: Leading experts will explore how epigenetic engineering can revolutionize T-cell therapy.

Visit Tandem Meetings News for more details: ow.ly/RPt150V0tTn